Denali Therapeutics (NASDAQ:DNLI) Issues Earnings Results

Key Points

• Denali Therapeutics beat quarterly estimates, reporting EPS of $0.37 versus analysts’ expected loss of $0.32 and revenue of $17.78 million versus $12.22 million expected.
• The stock rose 3.1% to $19.45 in Tuesday trading.
• Analysts have a consensus “Moderate Buy” rating and an average price target of $35.85.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.69, FiscalAI reports. The business had revenue of $17.78 million during the quarter, compared to analyst estimates of $12.22 million.

Denali Therapeutics Trading Up 3.1%

Shares of Denali Therapeutics stock traded up $0.59 during trading hours on Tuesday, reaching $19.45. The stock had a trading volume of 2,416,437 shares, compared to its average volume of 1,716,696. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of -6.85 and a beta of 1.02. Denali Therapeutics has a 1 year low of $13.75 and a 1 year high of $27.30. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $20.52 and a two-hundred day simple moving average of $21.24.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider directly owned 281,763 shares of the company's stock, valued at $7,063,798.41. The trade was a 1.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 9.70% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on DNLI. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, July 16th. JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics in a research report on Monday, July 13th. They issued an "overweight" rating and a $29.00 target price on the stock. Robert W. Baird set a $34.00 target price on shares of Denali Therapeutics in a report on Friday, August 7th. Wedbush reaffirmed an "outperform" rating and set a $26.00 price target on shares of Denali Therapeutics in a research report on Monday, July 13th. Finally, Morgan Stanley increased their price target on shares of Denali Therapeutics from $35.00 to $36.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Denali Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $35.85.

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company's research programs target conditions including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.